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Abstract
Background: Some clinical chemistry measurement 
methods are vulnerable to interference if hemolyzed 
serum samples are used. The aims of this study were: (1) to 
obtain updated information about how hemolysis affects 
clinical chemistry test results on different instrument plat-
forms used in Nordic laboratories, and (2) to obtain data 
on how test results from hemolyzed samples are reported 
in Nordic laboratories.
Methods: Four identical samples containing different 
degrees of hemolysis were prepared and distributed to 
145 laboratories in the Nordic countries. The laborato-
ries were asked to measure the concentration of cell-
free hemoglobin (Hb), together with 15 clinical chem-
istry analytes. In addition, the laboratories completed 
a questionnaire about how hemolyzed samples are 
handled and reported.
Results: Automated detection of hemolysis in all routine 
patient samples was used by 63% of laboratories, and 
88% had written procedures on how to handle hemolyzed 
samples. The different instrument platforms measured 
comparable mean Hb concentrations in the four samples. 
For most analytes, hemolysis caused a homogenous 
degree of interference regardless of the instrument plat-
form used, except for alkaline phosphatase (ALP), biliru-
bin (total) and creatine kinase (CK). The recommended 
cut-off points for rejection of a result varied substantially 
between the manufacturers. The laboratories differed in 
how they reported test results, even when they used the 
same type of instrument.
Conclusions: Most of the analytes were homogeneously 
affected by hemolysis, regardless of the instrument used. 
There is large variation, however, between the laborato-
ries on how they report test results from hemolyzed sam-
ples, even when they use the same type of instrument.
Keywords: analytical interference; hemoglobin; hemoly-
sis; laboratory errors; preanalytical phase.
Introduction
Hemolysis of blood samples is a pre-analytical challenge 
that often leads to sample rejection in medical laborato-
ries [1]. Hemolysis occurs when blood cells break down 
and the intracellular contents leak into the surrounding 
fluid [2]. When hemolyzed blood samples are analyzed 
in medical laboratories, the content released from the 
blood cells can interfere with the measurement proce-
dure, leading to erroneous results that may not reflect 
the patient’s clinical condition. How, and to what extent, 
hemolysis may affect test results depends on the analyte 
and the measurement method used [1].
Interference studies are performed to establish how 
much the various analytes, when measured by different 
methods, will be affected by hemolysis [3]. Based on the 
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results, instrument-specific cut-off points are determined 
to prevent hemolysis from significantly affecting the clini-
cal interpretation of laboratory results. Most instruments 
used in medical laboratories today can measure cell-free 
hemoglobin (Hb) in individual blood samples and trans-
fer the result to the laboratory information system (LIS). 
These Hb results may be combined with predefined Hb 
cut-off points, enabling the laboratories to automatically 
reject or comment upon test results significantly affected 
by hemolysis [4].
Cut-off points for rejection of samples are commonly 
recommended by the manufacturers of in vitro diagnos-
tic (IVD) analytical systems. The Clinical and Laboratory 
Standards Institute (CLSI) recommends that the laborato-
ries verify the intended usefulness, strengths and limita-
tions of manufacturer-derived cut-off points before they 
are implemented [5]. This is time and resource consuming 
for the laboratory, and may be difficult as manufacturers’ 
package inserts often lack information about experiment 
design and how the cut-off points were defined [6–8]. 
Consequently, many laboratories use the manufacturers’ 
cut-off points for hemolysis, without further verification 
studies [8].
The Nordic cooperation of External Quality Assurance 
(EQA) organizers, EQAnord, performed a large interfer-
ence study in 2002 to obtain data on the effect of hemolysis 
on analytical performance on different clinical chemistry 
instruments [9]. The aims of the current study were (1) to 
obtain updated information about how hemolysis affects 
clinical chemistry test results on different instrument 
platforms, and (2) to obtain data on how test results from 
hemolyzed samples are reported in medical biochemistry 
hospital laboratories in the Nordic countries.
Materials and methods
Preparation of samples
The blood was collected from eight healthy donors with identical 
ABO and RhD group at the Haukeland University Hospital blood 
bank, Bergen, Norway. The donors had provided informed written 
consent to the donation of blood. Ethical approval was not required 
for this quality assurance survey [10]. One Fenwal blood bag contain-
ing no anticoagulant (Fenwal Laboratories, Deerfield, IL, USA) and 
one lithium-heparin blood tube (BD Vacutainer Lithium-Heparin 
[17 IU/mL], BD, Plymouth, UK) were drawn from each blood donor. 
The blood bags were centrifuged after 3 h clotting time at room tem-
perature. After centrifugation, serum from all donors was mixed and 
divided into four pools.
The hemolysate added was prepared with lithium-heparin 
blood from the blood donors, stored for 2  h at −80 °C. The tubes 
were thawed for 1 h at 21 °C and centrifuged for 10 min at 1300 g at 
21 °C. The top layers from the eight tubes were mixed and used as 
hemolysate [11, 12]. The Hb concentration in the hemolysate and the 
four identical samples distributed to the participants was measured 
using a point-of-care instrument HemoCue Hb 201 +  (HemoCue, 
Ängelholm, Sweden). The instrument has an analytical coefficient 
of variation (CV) of 0.5% and is monitored twice a year by external 
quality controls. The Hb concentration in the hemolysate was 140.5 
g/L (n = 2). Sample 1  had no hemolysate added (baseline sample, 
mean Hb: 0.3 g/L, n = 3). Sample 2 had 2.8 mL hemolysate added to 
394  mL serum corresponding to a calculated Hb concentration of 
approximately 1 g/L (mean Hb: 1.3 g/L, n = 3), Sample 3 had 5.7 mL 
hemolysate added to 391  mL serum corresponding to a calculated 
Hb concentration of approximately 2 g/L (mean Hb: 2.3 g/L, n = 3) 
and Sample 4 had 11.3 mL hemolysate added to 386 mL serum cor-
responding to a calculated Hb concentration of approximately 4 g/L 
(mean Hb: 5.0 g/L, n = 3).
The four samples containing different degrees of hemolysis were 
distributed with cooling elements to the various EQA organizations 
with express shipment. Further shipment to the various laboratories 
was performed at ambient temperature.
Recruitment of participants and sample analysis
Invitation to participate in the study was sent to laboratories partici-
pating in clinical chemistry EQA-schemes in the Nordic countries by 
the local EQA organizations; the Danish Institute for External Quality 
Assurance for Laboratories in Health Care (DEKS), the External Qual-
ity Assurance in Laboratory Medicine in Sweden (Equalis), Icelandic 
Society for Clinical Biochemistry and Laboratory Medicine (ISLM), 
Labquality and the Norwegian Organization for Quality Improve-
ment of Laboratory Examinations (Noklus). A total of 294  Nordic 
medical biochemistry laboratories were invited. Of these, 145 agreed 
to participate and were sent four samples containing different 
degrees of hemolysis in November 2014. The laboratories were asked 
to measure and report the concentration of Hb and the following 15 
clinical chemistry analytes: alkaline phosphatase (ALP), bilirubin 
(total), calcium, chloride, cobalamin, creatine kinase (CK), folate, 
free thyroxine (FT4), γ-glutamyltransferase (GGT), glucose, lactate 
dehydrogenase (LDH), potassium, sodium, thyroid-stimulating hor-
mone (TSH) and uric acid.
All the laboratories were asked to analyze the samples in 
duplicate, on the fourth day after preparation of the samples, and 
report the mean value of each analyte. In addition, the laboratories 
completed a questionnaire about their procedures for handling and 
reporting hemolyzed samples, including two case studies (Figure 1).
Data analysis
Analyte concentration in Sample 1 (i.e. without hemolysis) 
was used as the baseline concentration. For each analyte, per-
cent change (bias%) was calculated according to the formula: 
bias% = 100 * (measured concentration – baseline concentration)/
baseline concentration, and a 95% confidence interval (CI) for the 
bias% was calculated. If the 95% CIs of bias% of two instrument 
groups did not overlap, the difference was considered statistically 
significant.
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The laboratories were asked to report the concentration of 
Hb in either a quantitative (g/L) or a semi-quantitative value (e.g. 
+/ + + / + + +, etc.), as applicable. All semi-quantitative Hb results 
were converted into quantitative values for further calculations. 
For example, if a laboratory with Beckman Coulter AU reported ++, 
which equals 1.00–2.00 g/L [13], the Hb result was converted into the 
mean value of the corresponding interval; i.e. 1.50 g/L. It was defined 
as “handled in accordance with manufacturer’s cut-off” if the labo-
ratory reported or reported with comment when the measured Hb 
value was below the manufacturer’s cut-off point or if the laboratory 
rejected or rejected with comment when the measured Hb value was 
above the manufacturer’s cut-off point. Manufacturer’s cut-off points 
were stated by the manufacturers in personal communications to the 
authors, however, the bias corresponding to the cut-offs and conse-
quently regarded as acceptable by the manufacturers, were not com-
municated. To check for consistency regarding the magnitude of bias 
regarded acceptable by manufacturers, we calculated the Hb concen-
trations giving a 10% bias for three analytes; CK, LDH and potassium, 
and investigated whether the manufacturers’ recommended cut-off 
points for rejection of a test result corresponded to the 10% bias. A 
10% bias was chosen as example as this value is commonly used as a 
cut-off point by the manufacturers of IVD analytical systems [14]. The 
concentration of Hb giving a bias of 10% was calculated using simple 
linear regression. Linearity was verified with plots and R2.
Data analyses were performed using Excel 2010.
Results
Procedures for detecting and handling 
hemolysis
Of the 294 laboratories invited to take part, 143 (49%) 
responded to the survey. The response rate in Denmark 
was 67% (32/48), Finland 22% (25/112), Iceland 100% 
(4/4), Norway 95% (53/56) and Sweden 39% (29/74) (see 
Supplementary Table 1 for distribution of instrument plat-
forms). Of these, 122 (85%) performed automated meas-
urement of the Hb concentration in the four blood samples 
received and reported a quantitative or semi-quantitative 
Hb concentration. The laboratories were asked in the 
questionnaire how they investigate and detect interfer-
ence by hemolysis in routine samples. Ninety laboratories 
(63%) stated that they measure Hb routinely in all patient 
samples; 88% (28/32) in Denmark, 69% (20/29) in Sweden, 
57% (30/53) in Norway, 44% (11/25) in Finland and 25% 
(1/4) in Iceland. Manual inspection to detect hemolysis 
was performed by 22 laboratories (15%), whereas 9% used 
manual inspection, followed by automated detection if 
hemolysis was suspected (Figure 2). Eighty-eight percent 
of the laboratories had written procedures for how to 
handle hemolyzed samples; 100% (32/32) in Denmark, 
96% (28/29) in Sweden, 88% (22/25) in Finland, 81% 
(43/53) in Norway and 25% (1/4) in Iceland.
Influence of hemolysis on analyte 
concentration
Clinical chemistry measurements in the four identical 
samples were carried out on 11 different instruments, pro-
duced by seven manufacturers; Abbott Architect (n = 23) 
Question 1A: If Sample 2 was analyzed in your laboratory, which action would you take for the following analytes.
Question 1B: Please answer this question if you chose to reject some of the results in question 1A: Imagine that Sample 2 was from a 2-year-
old child admitted to the Oncologic Department in your hospital. Thirty minutes after rejecting some of the results do you receive a call from
the requesting physician who asks for the non-reported results, arguing that the sampling was extremely difficult and claims that it is not
possible to get a new sample. Please specify below which ADDITIONAL results (if any) you would report.   
Question 2A: If Sample 3 was analyzed in your laboratory, which action would you take for the following analytes.
Question 2B: Please answer this question if you chose to reject some of the results in question 2A: Imagine that Sample 3 was from a 60-year-
old man who was admitted to the emergency department with acute chest pain. Ten minutes after rejecting some of the results do you receive
a call from the requesting physician who asks for the non-reported results, arguing that rapid results are very important for further treatment























Figure 2: How laboratories investigate and detect hemolysis 
interference in patient samples received for analysis.
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(Abbott Laboratories, Abbott Park, IL, USA), Beckman 
Coulter AU (n = 5) (Beckman Coulter, Brea, CA, USA), 
Beckman Coulter UniCel (n = 4) (Beckman Coulter, Brea, 
CA, USA), Ortho Vitros (n = 15) (Ortho Clinical Diagnos-
tics, Raritan, NJ, USA), Perkin Elmer AutoDelfia (n = 1) 
(Perkin Elmer, Turku, Finland), Roche Cobas (n = 52) 
(Roche Diagnostics, Mannheim, Germany), Roche 
Integra (n = 3) (Roche Diagnostics, Mannheim, Germany), 
Roche Modular (n = 8) (Roche Diagnostics, Mannheim, 
Germany), Siemens Advia (n = 17) (Siemens Healthcare 
Diagnostics, Deerfield, IL, USA), Siemens Dimension 
(n = 10) (Siemens Healthcare Diagnostics, Deerfield, IL, 
USA) and Thermo Scientific Konelab (n = 5) (Thermo Sci-
entific, Vantaa, Finland).
Hb was measured on the same clinical chemistry 
instruments as the other 15 analytes and the mean Hb 
concentrations were in accordance with the theoretical Hb 
concentrations calculated from the amount of Hb added 
to the sample material (see Methods section); Sample 1 
(n = 122): 0.02 g/L (95% CI −0.03, 0.07), Sample 2: 1.19 g/L 
(95% CI 0.64, 1.74), Sample 3: 2.17 g/L (95% CI 1.08, 3.26) 
and Sample 4: 4.18 g/L (95% CI 3.36, 5.00).
Table 1 shows the mean Hb concentrations and the 
average effect of hemolysis on test results (bias%) for 
Sample 2 and 3 for each of the 15 analytes for instrument 
groups with more than five participants. The interference 
caused by hemolysis on the mean test results for the dif-
ferent instruments was statistically significantly different 
for ALP, bilirubin (total) and CK in samples with Hb 1 g/L 
and 2 g/L (Table 1, Figure 3A, Supplementary Figure 1A 
and B). As an example, Sample 3 had a hemolysis of 2 g/L, 
which would cause the CK result to increase between 1.5% 
(Abbott Architect) and 25.6% (Siemens Dimension). For 
LDH, Ortho Vitros showed significantly lower concentra-
tions compared to the other instrument groups (Figure 3B). 
The results for all instruments and all samples are shown 
in Supplementary Table 2. Interferographs for all analytes 
are shown in Figure 3 and Supplementary Figure 1.
Cut-off points recommended by the 
manufacturers
Even though hemolysis affected most analyte results to the 
same degree throughout different instrument platforms, 
the recommended cut-off points for rejection of a result 
varied substantially between the manufacturers (Supple-
mentary Table 3). Using potassium as example, the bias 
from baseline in Sample 2 (i.e. 1 g/L) varied between 6.7% 
(Roche Modular) to 7.3% (Ortho Vitros) (Figure 3C). Simul-
taneously did the manufacturers’ recommended cut-off 
points for rejection of a test result vary from 0 (avoid all 
hemolyzed samples) (Siemens Advia/Dimension) to 1.25 
(Abbott Architect).
Hb concentrations giving a 10% bias were calculated 
across instrument platforms for CK, LDH and potassium. 
The manufacturers’ recommended cut-offs did commonly 
not coincide with the Hb concentration causing 10% bias 
as calculated by linear regression (Tables 2–4). Using LDH 
as example, Hb concentrations between 0.12 and 0.18 g/L 
correspond to a 10% bias on the different instrument plat-
forms (Table 3), while the manufacturers’ recommended 
cut-off points varied from 0 (i.e. avoid all hemolyzed 
samples; Abbott Architect, Siemens Advia and Dimen-
sion) to 1.00 g/L (Beckman Coulter). Linearity for CK, LDH 
and potassium was verified with plots and R2 and found 
good (R2 > 0.95).
How do laboratories handle results affected 
by hemolysis?
The laboratories report in the questionnaire that they 
would take some kind of action due to hemolysis in 
1%–2% of routine samples. The proportion of samples 
handled in accordance with the manufacturers’ cut-off 
points (see Table 5) varied between 65% (folate) and 100% 
(FT4, GGT and TSH) in Sample 2 (Hb concentration 1 g/L). 
For Sample 3 (Hb concentration 2 g/L), the proportion 
varied between 59% (CK) and 98% (TSH). Tables 2–4 show 
that even laboratories using the same instrument platform 
would take very different actions, for CK, LDH and potas-
sium, upon receiving identically hemolyzed samples. For 
example, all but two Roche Cobas instruments (48 out of 
50) measured a Hb concentration above 2 g/L in Sample 
3, which exceeds the manufacturer’s recommended rejec-
tion limit when measuring CK. Table 2 shows, however, 
that the laboratories could take any of the following 
actions; report (n = 7), report with comment (n = 12), reject 
(n = 5) and reject with comment (n = 24). Sample 3 would 
cause the LDH result to increase between 114.8% and 
152.3%, depending on the instrument used (Figure 3B). 
Twelve out of 122 laboratories (10%) would report this 
LDH concentration (Table 3), and comment on the result. 
The degree of hemolysis in Sample 2 (Hb concentration 1 
g/L) would increase the potassium result by a maximum of 
7.3% (Figure 3C), and 88 laboratories (72%) would reject the 
test result or reject the test result with comment (Table 4).
Laboratories that initially rejected the result due 
to hemolysis in the sample, would only to some extent 
release the result after a call from the requesting phy-
sician (Table  6). One-hundred of the 143 responding 
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laboratories (70%) would refuse to report a potassium 
result of 4.1  mmol/L in a hemolyzed sample causing 
the potassium result to increase by a maximum of 7.3% 
(Figure 3C). Even after learning from the requesting cli-
nician that the sample was from a 2-year-old oncologic 
patient with a very difficult phlebotomy case (Figure 1), 
59 (41%) would still refuse to report the result. A total of 
117 (82%) laboratories would refuse to report a potassium 
result if it increased 14% due to hemolysis (Figure 3C). 
After learning the sample was from a 60-year-old man 
admitted to the emergency department with acute chest 
pain (Figure 1), 91 (64%) would still refuse to report the 
result.
Discussion
This study provides updated information on the effect of 
hemolysis on clinical chemistry test results. Most of the 15 
analytes were similarly affected, regardless of the instru-
ment used. However, the laboratories differed widely on 
how they handled and reported the results.
The laboratories in our study reported that they would 
take some form of action due to hemolysis in 1%–2% of 
the samples received. This is in line with previous studies, 
ranging from 0.05% to 3.3% [7]. Eighty-eight percent of 
the laboratories had written procedures for how to handle 
hemolyzed samples. This is higher than what was found 
by Lippi et al. in a national Italian study, where 67 of 107 
laboratories (63%) followed a standardized procedure for 
management of hemolyzed specimens [15]. In the Italian 
study, 69% used visual inspection to detect hemolysis, 
while in our study, automated procedures were most com-
monly used. Guidelines are issued by different laboratory 
organizations [16–18], however, there is no harmonized 
procedure for how unsuitable samples should be handled 
across different laboratories worldwide [17]. However, 
there is a general consensus that automated detection of 
hemolysis should be used as visual inspection is highly 
unreliable [16, 17, 19].
The agreement between different instruments on 
measured Hb concentrations corresponds well with pre-
vious findings [7, 20–22]. To further harmonize measure-
ment of cell-free Hb concentrations across instruments, 
we advocate that laboratories should participate in EQA 
programs for serum indices.
We observed that even if different instrument plat-
forms were equally affected by hemolysis, the manufac-
turers gave different recommendations regarding when a 
sample should be rejected (see Tables 3 and 4 and Sup-
plementary Table 3). This means that following the manu-
facturers’ advice will not lead to harmonized handling of 
hemolyzed samples. The proportion of samples handled 
in accordance with manufacturers’ cut-off points varied, 
even for laboratories using the same assay. This indicates 
that Nordic laboratories have implemented other analyte-
specific cut-off points for hemolysis for some analytes 
than those provided by the manufacturer. This was also 
found in a Dutch multicenter evaluation [23]. In both an 
Australian and an American study, however, laboratories 
more often used the manufacturers’ cut-off points [24, 
25]. These findings demonstrate the lack of consensus on 
which acceptance criteria to use when determining cut-off 
points for rejection of samples. Acceptance limits can be 
based on clinical outcome, biological variation (reference 



























Abbott Architect (n = 21)
Beckman AU (n = 5)
Beckman Unicel (n = 3)
Ortho Vitros (n = 12)
Roche Cobas (n = 50)
Roche Integra (n = 3)
Roche Modular (n = 8)
Siemens Advia (n = 15)



























Abbott Architect (n = 21)
Beckman AU (n = 5)
Beckman Unicel (n = 3)
Ortho Vitros (n = 13)
Roche Cobas (n = 47)
Roche Integra (n = 2)
Roche Modular (n = 7)
Siemens Advia (n =16)



























Abbott Architect (n = 21)
Beckman AU (n = 4)
Beckman Unicel (n = 3)
Ortho Vitros (n = 14)
Roche Cobas (n = 51)
Roche Integra (n = 3)
Roche Modular (n = 8)
Siemens Advia (n = 17)
Siemens Dimension (n = 10)
Figure 3: Percent change from baseline, i.e. hemolysis interference, 
presented as interferographs; A: CK, B: LDH, C: potassium.
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change limit [ACL] [3, 26]), as well as the arbitrary 10% 
cut-off point commonly used by manufacturers and labo-
ratories [8, 27, 28].
Analytical test results from hemolyzed samples have 
also previously been reported heterogeneously. Lippi et al. 
[15] found that hemolyzed specimens were either reported 
with comment (54%), rejected and the requesting depart-
ment contacted for a new sample (27%), rejected with 
comment (16%) or the result corrected, depending on 
the degree of hemolysis (3%). Laboratories in the UK and 
Ireland would reject 40% of results above the cut-off point 
automatically [29]. Nikolac et al. [30] showed that 136 out 
of 159 laboratories (86%) would reject a potassium result 
in a sample with hemolysis of 0.5 g/L, while in our study, 
72% of laboratories would reject a potassium test result 
in a sample with hemolysis of 1 g/L. The different actions 
taken by laboratories may indicate that they might apply 
less stringent quality criteria for some analytes to prevent 
rejection of test results, and therefore to a larger extent 
rely on local performance studies or apply cut-off points 
based on clinical needs [23, 31–33].
In our study, more than 40% of laboratories still 
refused to report a potassium result that increased by 7%, 
even if they learned from the clinician that the result was 
important. It is questionable whether such a rigid prac-
tice is beneficial for the patient. Carraro et al. have argued 
that potassium results from hemolyzed samples should be 
reported with comment, due to the severity of a possible 
in vivo hemolysis [34]. The European Federation of Clini-
cal Chemistry and Laboratory Medicine (EFLM) Working 
Group for Preanalytical Phase states that it is acceptable to 
communicate hyper- or hypokalemia measured in mildly 
hemolyzed samples, when the bias is regarded as being 
not clinically relevant [17]. If a universal consensus for 
handling of hemolyzed samples should be agreed on, it 
is important that laboratories agree locally with clinicians 
on what interferences they can accept [35]. EQA organizers 
should offer schemes on interpretation and reporting of 
results from hemolyzed samples [36].
Limitations
We did not ask the laboratories or the manufacturers how 
they had defined their cut-off points. Another limitation 
was that only samples with analyte concentrations within 
normal intervals were used. However, spiking the samples 
to achieve abnormal concentrations could have added 
confounding interferences. Some of the 15 analytes (i.e. 
folate, LDH and potassium) are affected by hemolysis at 
lower thresholds than 1 g/L and including a sample with, 
for example, 0.5 g/L Hb, could have provided more accu-
rate data for these analytes.
Conclusions
Regardless of the instrument used, most of the analytes 
were similarly affected by hemolysis. The cut-off points 
recommended by the manufacturers, however, varied sig-
nificantly. The laboratories differed in how they reported 
test results, even when they used the same type of instru-
ment. It appears to be difficult to harmonize actions on 
how analytical test results from hemolyzed samples 
should be handled, due to a lack of consensus on which 
acceptance criteria to use. If a universal consensus for 
handling of hemolyzed samples should be agreed on, it 
is important that laboratories agree locally with clinicians 
on what interferences they can accept.
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